Graft-Versus-Host Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | CSL Behring, MaaT Pharma, Regimmune, Biocon, Xenikos, MaaT Pharma, Syndax Pharma

DelveInsight's "Graft-Versus-Host Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Graft-Versus-Host Disease, historical and forecasted epidemiology as well as the Graft-Versus-Host Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graft-Versus-Host Disease Market Forecast
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Graft-Versus-Host Disease Market Report:
• The Graft-Versus-Host Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to HRSA (2022), there were more than 8,000 allogeneic transplant patients in the US in 2013, and 9,498 transplants are anticipated in 2019, up from 9,509 in 2018
• In 2022, there were 51,540 GvHD cases in the 7MM as a whole. With about 23,150 cases in 2022, the United States had the most GvHD cases overall. During the study period (2019-2032), it is anticipated that these numbers will rise
• Acute GvHD incident cases were 10,340 in the 7MM, while chronic GvHD five-year prevalence was 23,080 in 2022, with an expected rise to 2032
• The total number of hematopoietic stem-cell and allogenic transplant cases in the United States were 24,510 and 10,260, respectively, in 2022, and are projected to rise by 2032
• Key Graft-Versus-Host Disease Companies: CSL Behring, MaaT Pharma, Regimmune, Biocon, Xenikos, MaaT Pharma, Syndax Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma Korea, Inc., Mesoblast, Inc., Incyte Corporation, and others
• Key Graft-Versus-Host Disease Therapies: CSL 964 AAT (zemaira), MaaT013, RGI-2001, Itolizumab, T-Guard, MaaT013, Axatilimab, TQ 05105, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Itacitinib, and others
• About 4,780 and 17,210 instances of aGvHD and cGvHD, respectively, received first-line care in the US in 2022. By 2032, more of these cases are anticipated, according to the report
• The Graft-Versus-Host Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft-Versus-Host Disease pipeline products will significantly revolutionize the Graft-Versus-Host Disease market dynamics.

Graft-Versus-Host Disease Overview
Graft-versus-host disease (GvHD) is an immune disorder that develops after an allogeneic bone marrow transplant (stem cell transplant) when immune cells (T cells) from the donor (also referred to as the graft or graft cells) attack the recipient patient host's tissues (healthy cells).

Get a Free sample for the Graft-Versus-Host Disease Market Report
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graft-Versus-Host Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Graft-Versus-Host Disease Epidemiology Segmentation:
The Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Graft-Versus-Host Disease
• Prevalent Cases of Graft-Versus-Host Disease by severity
• Gender-specific Prevalence of Graft-Versus-Host Disease
• Diagnosed Cases of Episodic and Chronic Graft-Versus-Host Disease

Download the report to understand which factors are driving Graft-Versus-Host Disease epidemiology trends @ Graft-Versus-Host Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graft-Versus-Host Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft-Versus-Host Disease market or expected to get launched during the study period. The analysis covers Graft-Versus-Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Graft-Versus-Host Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graft-Versus-Host Disease Therapies and Key Companies
• CSL 964 AAT (zemaira): CSL Behring
• MaaT013: MaaT Pharma
• RGI-2001: Regimmune
• Itolizumab: Biocon
• T-Guard: Xenikos
• MaaT013: MaaT Pharma
• Axatilimab: Syndax Pharmaceuticals
• TQ 05105: Chia Tai Tianqing Pharmaceutical Group
• Defibrotide: Jazz Pharmaceuticals
• Ibrutinib: Pharmacyclics LLC.
• Panobinostat (LBH589): Novartis
• Natalizumab: Biogen
• Methoxsalen: Mallinckrodt
• Prograf: Astellas Pharma Korea, Inc.
• Prochymal®: Mesoblast, Inc.
• Itacitinib: Incyte Corporation

Discover more about therapies set to grab major Graft-Versus-Host Disease market share @ Graft-Versus-Host Disease Treatment Market
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graft-Versus-Host Disease Market Strengths
• Pipeline of GvHD is very robust and several late stage assets are expected to enter in to the market very soon. GvHD pipeline consists of small molecules, monoclonal and Bi-specific antibody, stem cell therapy, recombinant fusion protein etc. which will provide the patients and physicians more options in future.

Graft-Versus-Host Disease Market Opportunities
• Several upcoming therapies have received Orphan designations, therapies can get accelerated approval time, 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees and others. Company can also go for premium pricing as well.

Scope of the Graft-Versus-Host Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Graft-Versus-Host Disease Companies: CSL Behring, MaaT Pharma, Regimmune, Biocon, Xenikos, MaaT Pharma, Syndax Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma Korea, Inc., Mesoblast, Inc., Incyte Corporation, and others
• Key Graft-Versus-Host Disease Therapies: CSL 964 AAT (zemaira), MaaT013, RGI-2001, Itolizumab, T-Guard, MaaT013, Axatilimab, TQ 05105, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Itacitinib, and others
• Graft-Versus-Host Disease Therapeutic Assessment: Graft-Versus-Host Disease current marketed and Graft-Versus-Host Disease emerging therapies
• Graft-Versus-Host Disease Market Dynamics: Graft-Versus-Host Disease market drivers and Graft-Versus-Host Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graft-Versus-Host Disease Unmet Needs, KOL's views, Analyst's views, Graft-Versus-Host Disease Market Access and Reimbursement

To know more about Graft-Versus-Host Disease companies working in the treatment market, visit @ Graft-Versus-Host Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Graft-Versus-Host Disease Market Report Introduction
2. Executive Summary for Graft-Versus-Host Disease
3. SWOT analysis of Graft-Versus-Host Disease
4. Graft-Versus-Host Disease Patient Share (%) Overview at a Glance
5. Graft-Versus-Host Disease Market Overview at a Glance
6. Graft-Versus-Host Disease Disease Background and Overview
7. Graft-Versus-Host Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Graft-Versus-Host Disease
9. Graft-Versus-Host Disease Current Treatment and Medical Practices
10. Graft-Versus-Host Disease Unmet Needs
11. Graft-Versus-Host Disease Emerging Therapies
12. Graft-Versus-Host Disease Market Outlook
13. Country-Wise Graft-Versus-Host Disease Market Analysis (2019-2032)
14. Graft-Versus-Host Disease Market Access and Reimbursement of Therapies
15. Graft-Versus-Host Disease Market Drivers
16. Graft-Versus-Host Disease Market Barriers
17. Graft-Versus-Host Disease Appendix
18. Graft-Versus-Host Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Graft-Versus-Host Disease Pipeline https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Graft-Versus-Host Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Graft-Versus-Host Disease market. A detailed picture of the Graft-Versus-Host Disease pipeline landscape is provided, which includes the disease overview and Graft-Versus-Host Disease treatment guidelines.
Graft-Versus-Host Disease Epidemiology https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graft-Versus-Host Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Graft-Versus-Host Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.